Lymphoma

John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL

John Kuruvilla joins us to discuss the presentation a the ASCO20 Virtual Meeting of the results of the KEYNOTE-204 trial, the first positive phase III trial of an anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. Questions 1. What are the unmet needs in the treatment of classical Hodgkin lymphoma? (0:06) 2. […]

Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care

European Oncology and Haematology. 2019:15(1):53–63 DOI: https://doi.org/10.17925/EOH.2019.15.1.53

Hodgkin lymphoma is a B-cell lymphoma that predominantly affects adults between 20–40 years of age, with a second incidence peak in those 55 years of age or older.1,2 It is also the most common form of lymphoma in adolescents, occurring in nearly two-thirds of patients with lymphoma between the ages of 15–19.3 Overall, the annual incidence of […]

Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Large B-cell Lymphoma – Latest Data from the ZUMA-1 Study

European Oncology & Haematology, 2019;15(1):16–7 DOI: https://doi.org/10.17925/EOH.2019.15.1.16

Large B-cell lymphoma includes diffuse large B-cell lymphomas, primary mediastinal B-cell lymphoma and transformed follicular lymphoma. These have historically been treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). High-dose salvage chemotherapy and autologous stem-cell transplantation (SCT) can be used in case of relapse, however, patients who fail R-CHOP or relapse following SCT have a […]

Theodoros P Vassilakopoulos, MD, PhD, EHA 2019 – Exciting new developments in Hodgkin lymphoma

At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma. Questions 1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05) 2. What is the role of brentuximab vedotin in the current […]

Andrea Gallamini, EHA 2019 – Three-year Update of the ECHELON-1 Study

We are joined by Andrea Gallamini, at EHA 2019 to discuss his presentation on frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Questions 1. Could you tell us a little about the ECHELON-1 study and its findings? (0:05) 2. What have we learned from the 3-year […]

Eva Domingo Domènech, EHA 2019 – The Phase II CHECKMATE 205 Study

We are joined by Eva Domingo Domènech at EHA 2019 to discuss her presentation on nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: 2-year extended follow-up from cohort D of the phase II CHECKMATE 205 study. Questions 1. What are the major unmet needs in the treatment of advanced stage […]

Current Therapeutic Options in Waldenström Macroglobulinemia

Oncology & Hematology Review. 2019;15(1):39–47 DOI: https://doi.org/10.17925/OHR.2019.15.1.39

Waldenström macroglobulinemia (WM) is an indolent lymphoma characterized by the presence of a circulating monoclonal immunoglobulin M (IgM) protein of any size and lymphoplasmacytic infiltrate in the bone marrow.1 It lies within a continuous spectrum of disorders associated with a monoclonal IgM protein in the serum, with the precursor disease, IgM monoclonal gammopathy of undetermined […]

Annalisa Chiappella, EHA 2018 – TP53 Mutations in DLBCL: the FIL-DLCL04 Study

Annalisa Chiapella from Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Italy talks to touchONCOLOGY about patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation, and the aims and findings of the FIL-DLCL04 study to help tackle this. 1. Could you tell us a little about the FIL-DLCL04 study […]